CSIMarket
 
Intra cellular Therapies Inc   (ITCI)
Other Ticker:  
 
 
Price: $65.3700 $0.59 0.911%
Day's High: $65.98 Week Perf: 1.55 %
Day's Low: $ 64.75 30 Day Perf: -12.71 %
Volume (M): 489 52 Wk High: $ 76.11
Volume (M$): $ 31,940 52 Wk Avg: $60.99
Open: $64.97 52 Wk Low: $44.90



 Market Capitalization (Millions $) 6,254
 Shares Outstanding (Millions) 96
 Employees 200
 Revenues (TTM) (Millions $) 464
 Net Income (TTM) (Millions $) -140
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Intra Cellular Therapies Inc
Intra cellular Therapies Inc (ITCI) is a biopharmaceutical company that is focused on the discovery and development of molecular drugs that target the central nervous system (CNS). The company's mission is to develop innovative therapies that can improve the lives of patients with serious neurological and psychiatric disorders. The company is based in New York and was founded in 200

ITCI's therapies are based on the science of phospholipid signaling. Phospholipids are important molecules that are present in the membranes of cells. They play a key role in cell to cell communication by signaling within and between cells. ITCI has developed drug candidates that target specific pathways in the brain that are controlled by these signaling molecules. These pathways have been implicated in a range of psychiatric and neurological disorders including schizophrenia, bipolar disorder, depression, and Alzheimer's disease.

The company's lead drug candidate is Lumateperone, which is an oral medicine that has been developed for the treatment of schizophrenia. It is designed to balance the activity of neurotransmitters in the brain, which can help to reduce the symptoms of schizophrenia, such as hallucinations and delusions. Lumateperone has completed three phase-3 clinical trials, and the results have been positive. The drug was granted FDA approval in December 2019.

ITCI has also developed other drug candidates for the treatment of major depressive disorder, bipolar disorder, and other neurological conditions such as Alzheimer's disease. The company has a deep pipeline of CNS-focused drug candidates, which is supported by a strong intellectual property portfolio.

In addition to its drug development efforts, ITCI is also engaged in research and development of digital therapeutics. These are software-based interventions that are designed to improve patient outcomes by providing targeted support, education, and engagement. ITCI is exploring the potential for digital therapeutics to complement its drug therapies.

In summary, Intra cellular Therapies Inc is a biopharmaceutical company that is focused on the discovery and development of innovative therapies for serious neurological and psychiatric disorders. The company has developed drug candidates that target specific pathways in the brain that are controlled by phospholipid signaling. These therapies have the potential to improve patient outcomes and fill unmet medical needs in this area.


   Company Address: 430 East 29th Street New York 10016 NY
   Company Phone Number: 440-9333   Stock Exchange / Ticker: NASDAQ ITCI
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Intra Cellular Therapies Inc

Intra Cellular Therapies Inc Reports a Loss of $-0.29 per Share in Q4 of 2023

In the financial news report for the October to December 31, 2023 time-frame, Intra Cellular Therapies Inc (ITCI) reported a loss of $-0.29 per share. This is an improvement compared to a loss of $-0.41 per share in the same period a year ago and a surge from a loss of $-0.25 per share in the previous reporting season.
Despite the loss per share, ITCI experienced strong revenue growth, with a 50.336% increase to $132.10 million from $87.87 million in the corresponding reporting season a year before. Sequentially, revenue also surged by 4.697% from $126.17 million.

Intra Cellular Therapies Inc

Robust Revenue and Reduced Losses Propel Intra Cellular Therapies Inc to Stand Out in Major Pharmaceutical Preparations Industry

Investing in the stock market can be a roller coaster ride, with ups and downs that can leave even the most experienced investors feeling uneasy. However, there are times when the market provides a glimmer of hope, a moment when a company stands out from the crowd and shows promising signs of growth. Intra Cellular Therapies Inc is one such company that has recently caught the attention of many investors.
In its July to September 2023 span, Intra Cellular Therapies Inc experienced an extraordinary revenue growth of 75.557%, reaching a total of $126.17 million. This incredible growth has helped the company reduce its losses to $-0.25 per share, a significant improvement from the $-0.57 per share in the same reporting period a year before. This remarkable performance is even more impressive considering that the remainder of the Major Pharmaceutical Preparations industry witnessed a contraction of -5.26% in their business.

Intra Cellular Therapies Inc

Intra Cellular Therapies Inc Boosts Revenue and Trims Losses in Q2 2023, Surpassing Industry Peers


Introduction
Intra Cellular Therapies Inc. (ITCI) recently released its financial results for the second quarter of 2023, highlighting significant revenue growth and a reduction in losses per share. In this article, we will interpret the company's performance, outline the key facts, and speculate on how these results may impact the company going forward.
Strong Revenue Growth and Earnings Improvement
Over the past quarter, Intra Cellular Therapies Inc. witnessed an impressive revenue growth, with an increase of 99.341% to reach $110.79 million. This growth was a substantial improvement compared to the corresponding quarter last year. It is worth mentioning that during the same time, industry peers in the Major Pharmaceutical Preparations sector experienced an average top-line growth of 5.28%.

Intra Cellular Therapies Inc

Despite a Remarkable Surge in Revenue, Intra Cellular Therapies Inc (ITCI) Struggles to Break Even

Intra Cellular Therapies Inc is a biopharmaceutical company that focuses on developing and commercializing innovative drugs for the treatment of central nervous system (CNS) disorders. The company's pipeline includes several potential treatments for schizophrenia, bipolar disorder, and other CNS disorders, all of which aim to address significant unmet medical needs.
The January to March 31, 2023 period was a significant one for Intra Cellular Therapies Inc, as the company announced impressive revenue growth of 172.334% year-on-year. In total, the company's revenue for the period amounted to $95.31 million, a substantial increase compared to the same period in the previous year. Despite the impressive revenue growth, the company did experience a net loss, with a shortfall of $-0.46 per share.






 

Intra Cellular Therapies Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Intra Cellular Therapies Inc does not provide revenue guidance.

Earnings Outlook
Intra cellular Therapies Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com